NASDAQ:ACHV

Achieve Life Sciences - ACHV Stock Forecast, Price & News

$3.44

-0.14 (-3.91%)

(As of 10/5/2022 12:00 AM ET)

Add

Compare

Today's Range: $3.39
▼
$3.55
50-Day Range: $3.29
▼
$5.64
52-Week Range: $3.19
▼
$9.06

Volume: 15,862 shs
Average Volume: 28,602 shs
Market Capitalization: $33.30 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $25.33

Achieve Life Sciences MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 641.3% Upside
$25.50 Price Target
Short Interest: Bearish
3.40% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($3.88) to ($2.83) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.53 out of 5 stars

Medical Sector

873rd out of 1,072 stocks

Diagnostic Substances Industry

10th out of 16 stocks

3.5

Analyst's Opinion

Consensus Rating
Achieve Life Sciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $25.50, Achieve Life Sciences has a forecasted upside of 641.3% from its current price of $3.44.
Amount of Analyst Coverage
Achieve Life Sciences has received no research coverage in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
3.40% of the outstanding shares of Achieve Life Sciences have been sold short.
Short Interest Ratio / Days to Cover
Achieve Life Sciences has a short interest ratio ("days to cover") of 7.6.
Change versus previous month
Short interest in Achieve Life Sciences has recently increased by 0.03%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Achieve Life Sciences does not currently pay a dividend.
Dividend Growth
Achieve Life Sciences does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ACHV.

0.0

News and Social Media Coverage

Search Interest
Only 2 people have searched for ACHV on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Achieve Life Sciences insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 1.00% of the stock of Achieve Life Sciences is held by insiders.
Percentage Held by Institutions
Only 21.11% of the stock of Achieve Life Sciences is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Achieve Life Sciences are expected to grow in the coming year, from ($3.88) to ($2.83) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Achieve Life Sciences is -1.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Achieve Life Sciences is -1.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Achieve Life Sciences has a P/B Ratio of 1.16. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Achieve Life Sciences (NASDAQ:ACHV) Stock

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.

Receive ACHV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Achieve Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

ACHV Stock News Headlines

September 27, 2022 | finance.yahoo.com

Achieve Announces Completion of Target Enrollment in the Phase 3 ORCA-3 Trial of Cytisinicline for Smoking Cessation

September 7, 2022 | finance.yahoo.com

Achieve Life Sciences Announces Participation at Fall Investor Conferences

August 15, 2022 | finance.yahoo.com

ACHV: Autumn Enrollment Completion for ORCA-3

August 14, 2022 | investing.com

Achieve Life Sciences Misses Q2 EPS by 27c

August 12, 2022 | seekingalpha.com

Achieve Life Sciences, Inc. (ACHV) CEO John Bencich on Q2 2022 Results - Earnings Call Transcript

August 11, 2022 | finance.yahoo.com

Achieve Reports Financial Results for Second Quarter 2022 and Provides Corporate Update

July 28, 2022 | finance.yahoo.com

Achieve Life Sciences to Announce Second Quarter Financial Results and Host Conference Call and Webcast on August 11, 2022

July 19, 2022 | morningstar.com

Achieve Life Sciences Inc - Stock Quote ACHV

July 2, 2022 | morningstar.com

Achieve Life Sciences Announces Granting of New Hire Inducement Awards | Morningstar

July 1, 2022 | finance.yahoo.com

Achieve Life Sciences Announces Granting of New Hire Inducement Awards

June 29, 2022 | seekingalpha.com

Achieve Life Sciences begins phase 2 trial testing cytisinicline for nicotine e-cigarette cessation

June 29, 2022 | finance.yahoo.com

Achieve Life Sciences Announces Initiation of Phase 2 ORCA-V1 Clinical Trial Evaluating Cytisinicline for Nicotine e-cigarette Cessation

June 21, 2022 | finance.yahoo.com

Achieve Life Sciences Announces Participation at H.C. Wainwright 1st Annual Mental Health Conference

June 3, 2022 | morningstar.com

Achieve Life Sciences Inc - Stock News

June 1, 2022 | finance.yahoo.com

Achieve Life Sciences Awarded Grant from the National Institutes of Health to Conduct Phase 2 Trial of Cytisinicline in Nicotine e-cigarette Users

May 26, 2022 | finance.yahoo.com

Achieve Life Sciences Announces Participation at LD Micro Invitational Conference

May 13, 2022 | finance.yahoo.com

ACHV: First Quarter 2022 Results

May 13, 2022 | finance.yahoo.com

Achieve Life Sciences Announces Participation at Best Ideas Virtual Investor Conference

May 13, 2022 | uk.investing.com

Achieve Life Sciences Tops Q1 EPS by 1c

May 13, 2022 | seekingalpha.com

Achieve Life Sciences, Inc. (ACHV) CEO John Bencich on Q1 2022 Results - Earnings Call Transcript

May 13, 2022 | finance.yahoo.com

Achieve Reports Financial Results for First Quarter 2022 and Provides Corporate Update

May 5, 2022 | finance.yahoo.com

Health Check: How Prudently Does Achieve Life Sciences (NASDAQ:ACHV) Use Debt?

April 28, 2022 | finance.yahoo.com

ACHV: Topline Data from ORCA-2 Smoking Cessation Trial

April 27, 2022 | finance.yahoo.com

Achieve Life Sciences Aces Pivotal Cytisinicline Study In Smoking Cessation

April 27, 2022 | marketwatch.com

Achieve Life Sciences Reports Positive Phase 3 Smoking-Cessation Study >ACHV

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive ACHV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Achieve Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

ACHV Company Calendar

Last Earnings: 8/11/2022
Today: 10/06/2022
Next Earnings (Estimated): 11/08/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Diagnostic substances
Sub-Industry: Biotechnology
Sector: Medical
Current Symbol: NASDAQ:ACHV
CUSIP: 68230A10
CIK: 949858
Web: achievelifesciences.com
Phone: (604) 210-2217
Fax: 425-686-1600
Employees: 16
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $25.50
High Stock Price Forecast: $27.00
Low Stock Price Forecast: $24.00
Forecasted Upside/Downside: +636.4%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.35)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-33,150,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -131.02%
Return on Assets: -79.75%

Debt

Debt-to-Equity Ratio: 1.17
Current Ratio: 5.81
Quick Ratio: 5.81

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.97 per share
Price / Book: 1.16

Miscellaneous

Outstanding Shares: 9,680,000
Free Float: 9,585,000
Market Cap: $33.30 million
Optionable: Not Optionable
Beta: 1.27

Key Executives

Dr. Richard A. B. Stewart (Age 63)
Exec. Chairman
Comp: $660k

Mr. John A. Bencich M.B.A. (Age 45)
CEO & Director
Comp: $767.25k

Dr. Cindy Jacobs M.D. (Age 64)
Ph.D., Pres, Chief Medical Officer & Director
Comp: $668.8k

Mr. Jerry Wan (Age 40)
Principal Accounting Officer

Dr. Anthony Clarke (Age 66)
Chief Scientific Officer

Ms. Jaime Xinos
Exec. VP of Commercial

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ACHV Stock - Frequently Asked Questions

Should I buy or sell Achieve Life Sciences stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Achieve Life Sciences in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ACHV shares.
View ACHV analyst ratings or view top-rated stocks.
What is Achieve Life Sciences' stock price forecast for 2022?: 1 equities research analysts have issued 12-month target prices for Achieve Life Sciences' stock. Their ACHV share price forecasts range from $24.00 to $27.00. On average, they expect the company's share price to reach $25.50 in the next twelve months. This suggests a possible upside of 641.3% from the stock's current price.
View analysts price targets for ACHV or view top-rated stocks among Wall Street analysts.
How have ACHV shares performed in 2022?: Achieve Life Sciences' stock was trading at $7.78 at the beginning of the year. Since then, ACHV shares have decreased by 55.8% and is now trading at $3.44.
View the best growth stocks for 2022 here.
When is Achieve Life Sciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 8th 2022.
View our ACHV earnings forecast.
How were Achieve Life Sciences' earnings last quarter?: Achieve Life Sciences, Inc. (NASDAQ:ACHV) issued its quarterly earnings results on Thursday, August, 11th. The biopharmaceutical company reported ($1.08) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.79) by $0.29. During the same period in the previous year, the company earned ($1.53) EPS.

When did Achieve Life Sciences' stock split?: Achieve Life Sciences shares reverse split on Friday, July 31st 2020. The 1-20 reverse split was announced on Thursday, July 30th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, July 30th 2020. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.
What other stocks do shareholders of Achieve Life Sciences own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Achieve Life Sciences investors own include Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Gran Tierra Energy (GTE), Bionano Genomics (BNGO), Novan (NOVN), Aeterna Zentaris (AEZS), Zosano Pharma (ZSAN), CNBX Pharmaceuticals (CNBX), KushCo (KSHB) and Pennsylvania Real Estate Investment Trust (PEI).
What is Achieve Life Sciences' stock symbol?: Achieve Life Sciences trades on the NASDAQ under the ticker symbol "ACHV."
How do I buy shares of Achieve Life Sciences?: Shares of ACHV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Achieve Life Sciences' stock price today?: One share of ACHV stock can currently be purchased for approximately $3.44.
How much money does Achieve Life Sciences make?: Achieve Life Sciences (NASDAQ:ACHV) has a market capitalization of $33.30 million. The biopharmaceutical company earns $-33,150,000.00 in net income (profit) each year or ($3.35) on an earnings per share basis.
How can I contact Achieve Life Sciences?: Achieve Life Sciences' mailing address is 1040 WEST GEORGIA STREET SUITE 1030, VANCOUVER BC, V6E 4H1. The official website for the company is achievelifesciences.com. The biopharmaceutical company can be reached via phone at (604) 210-2217, via email at jwong@bplifescience.com, or via fax at 425-686-1600.

This page (NASDAQ:ACHV) was last updated on 10/6/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Achieve Life Sciences - ACHV Stock Forecast, Price & News

Achieve Life Sciences MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

Search Interest

Company Ownership

Earnings and Valuation

About Achieve Life Sciences (NASDAQ:ACHV) Stock

ACHV Stock News Headlines

ACHV Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

ACHV Stock - Frequently Asked Questions

MarketBeat Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources

Overall MarketRank^™